Other studies suggested that a high dose of tamoxfein (approximately four fold to eight fold higher than that for ERα-positive breast cancers) exhibits anti-tumor activity in ERα-negative cancer cells such as glioma, melanoma and pancreatic carcinoma [41–43]. Here, ESR1 is linked to breast cancer.